Key result
Proteomic profiling identified S100-A8, S100-A9, and Dermcidin as upregulated in active disease muscles and selectively present in the sera of FSHD patients compared to controls.
Why the study?
Detecting DUX4 and quantifying disease progression in FSHD is extremely challenging, increasing the need for surrogate biomarkers.
Does proteomic analysis of muscle microdialysates identify circulating biomarkers for Facioscapulohumeral Muscular Dystrophy?
Observational (n=10)
Does proteomic analysis of muscle microdialysates identify circulating biomarkers for Facioscapulohumeral Muscular Dystrophy?
Proteomic analysis of muscle microdialysates identified S100-A8, S100-A9, and Dermcidin as potential tissue and circulating biomarkers for active Facioscapulohumeral Muscular Dystrophy.
Answers are grounded in this paper and cite their sources.
Supports proteomic biomarker exploration in FSHD; hypothesis-generating and requires validation before clinical adoption.
in skeletal muscle. Detecting DUX4 and quantifying disease progression in FSHD is extremely challenging, thus increasing the need for surrogate biomarkers. We applied a shotgun proteomic approach with two different setups to analyze the protein repertoire of interstitial fluids obtained from 20 muscles in different disease stages classified by magnetic resonance imaging (MRI) and serum samples from 10 FSHD patients. A total of 1156 proteins were identified in the microdialysates by data independent acquisition, 130 of which only found in muscles in active disease stage. Proteomic profiles were able to distinguish FSHD patients from controls. Two innate immunity mediators (S100-A8 and A9) and Dermcidin were upregulated in muscles with active disease and selectively present in the sera of FSHD patients. Structural muscle and plasminogen pathway proteins were downregulated. Together with the upstream inhibition of myogenic factors, this suggests defective muscle regeneration and increased fibrosis in early/active FSHD. Our MRI targeted exploratory approach confirmed that inflammatory response has a prominent role, together with impaired muscle regeneration, before clear muscle wasting occurs. We also identified three proteins as tissue and possibly circulating biomarkers in FSHD.
No takes yet. Share an insight, caveat, or question.
Carregari et al. (2020) conducted an observational in Facioscapulohumeral Muscular Dystrophy (n=10). Facioscapulohumeral Muscular Dystrophy (FSHD) vs. Controls was evaluated on Differentially expressed proteins in muscle microdialysates and serum. Proteomic profiling identified S100-A8, S100-A9, and Dermcidin as upregulated in active disease muscles and selectively present in the sera of FSHD patients compared to controls.
Synapse has enriched 10 related papers. Consider them for comparative context: